Dr. Christopher Robert Flowers, MD

Dr. Flowers practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Flowers' NPI, 1174630503, was assigned on August 23, 2006. Dr. Flowers graduated from Stanford University School Of Medicine in 1997. Dr. Flowers holds Texas license S8306.

Dr. Flowers' primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Flowers' primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Flowers practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Flowers' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Flowers is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Flowers' licenses on file in 10 states: Texas, Florida, Arizona, Georgia, Tennessee, Louisiana, Alabama, Mississippi, Oklahoma and Washington.

Dmand AI lists lymphoma and multiple myeloma among the conditions Dr. Flowers treats.

CMS data shows 159 Medicare services from Dr. Flowers across 2 procedure codes in 2024, for 41 Medicare patients. Medicare paid $14,855 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 41 Medicare patients who saw Dr. Flowers in 2024. The largest group is 65 to 74, with 20 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 3.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Flowers' median patient age at 68, with 44% women.

In 2024, Dr. Flowers wrote 31 Medicare Part D claims. 97% of them were for generic drugs. CMS names the drug for 14 of them, across 1 drug with 11 or more claims each, at $341 in total drug cost. In 2019, CMS named 196 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Flowers for performance year 2024, reported as part of a group. Dr. Flowers accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 133 papers to Dr. Flowers, published from 2004 to 2022. 2013 was the busiest year, with 14. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Large B-Cell, Diffuse and Rituximab. Dr. Flowers has published most often in Cancer. Dr. Flowers' most frequent co-authors are Loretta J. Nastoupil, MD, Sagar Lonial, MD and Amelia A. Langston, MD.

Dmand AI links Dr. Flowers to 7 clinical trials, 2 of them phase 1/2 studies. 2 are still active or recruiting. Conditions studied include Lymphoma, Non-Hodgkin, Lymphoma, Follicular and Lymphoma, Mantle-Cell. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 186 general payments to Dr. Flowers from 22 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 71% of the total. Genentech, Inc. paid the most, $205,796. It also lists 49 research payments totaling $46,024 from 2016 to 2025.

Dr. Flowers serves on Committee on Appropriateness Criteria Expert Panel on Radiation Oncology - Lymphoma American College of Radiology and Guideline Development Group American Cancer Society.

Dr. Flowers graduated from Stanford University School Of Medicine in 1997.

Dr. Flowers is in network with 7 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. POS plans come from the most carriers, 4. Check the plan with the practice before a visit.